news of the space. Herantis recently started the extension study for CDNF to study longer terms effects of CDNF AND they're going to announce safety/tolerability data at AD/PD 2019 in late March. Full topline will be early 2020.

And there is indeed renewed major interest in the neurotrophic factor space. A GDNF gene therapy trial is gonna start this year. Remember ALL scientific literature suggests MANF superior to all.

I think partnering with IDEA is the start of the major major MANF partnership with BP we've all been waiting for. Trusted, talented eyes turning our way.

https://scienceofparkinsons.com/2019/01/10/2019/